Expert NetworkExpert InterviewJNJ

Slingshot members are talking to an expert! The topic is:

Second Look: Discussing the recent FDA approval of TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options for adult patients with moderate to severe Crohn's disease

Executed on:Apr 1, 2025 4:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: GI Alliance
  • Gastroenterologist at GI Alliance.
  • Currently manages 100 patients with ulcerative colitis.
  • Clinical interests include inflammatory bowel diseases and he has served as Site Principal Investigator for multiple phase I-IV clinical trials in Crohn’s disease and ulcerative colitis. 

Interview Goal

This conversation will focus on the Crohn's disease landscape and the recent approval of Tremfya (guselkumab) in treating Crohn's disease.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.